首页 › 转移性癌症 › 俄克拉荷马州 › Oklahoma City
Oklahoma City OK 转移性癌症临床试验
16项针对 转移性癌症的研究正在 Oklahoma City及周边约 30 英里内的站点招募参与者。打开研究详情可查看入选标准及联系研究团队的方式。
官方研究文本（英文）
正在为研究招募参与者？将此页面置顶展示 — $99 / 30天 →
BEACON-1: Study of AVZO-103 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Urothelial Cancer or Other Solid Tumors (AVZO-103-1001)
招募中1/2 期
- Avenzo Therapeutics Recruiting Site, Oklahoma City
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
招募中1/2 期
- University of Oklahoma, Oklahoma City
Testing the Addition of an Anti-Cancer Drug, ZEN003694, to the Usual Chemotherapy Treatment (Capecitabine) for Metastatic or Unresectable Cancers
招募中1 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Three-Part Phase 3 Study of Sofetabart Mipitecan in Participants With Platinum-Resistant (Part A) and Platinum-Sensitive (Parts B and C) Ovarian Cancer
招募中3 期
- University of Oklahoma Health Sciences Center, Stephenson Cancer Center, Oklahoma City
Study of Elironrasib and Daraxonrasib as Monotherapies and Combination Therapy in Participants With Advanced KRAS G12C Mutant Solid Tumors
招募中1/2 期
- University of Oklahoma, Oklahoma City
Personalized Antibody-Drug Conjugate Therapy Based on RNA and Protein Testing for the Treatment of Advanced or Metastatic Solid Tumors (The ADC MATCH Screening and Treatment Trial)
招募中2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
招募中1 期
- University of Oklahoma - Health Sciences Center, Oklahoma City
Studying the Safety and Determining the Optimal Dose of Novobiocin in Patients With Tumors That Have Alterations in DNA Repair Genes
招募中1 期
- University of Oklahoma Health Sciences Center, Oklahoma City
Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness
招募中1/2 期
- University of Oklahoma Health Sciences Center, Oklahoma City
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
招募中1/2 期
- Stephenson Cancer Center, Oklahoma City
Dose Escalation/Expansion Study of Mavrostobart (PT199), an Anti-CD73 mAb, Administered Alone and in Combination With a PD-1 Inhibitor or Chemotherapy (the MORNINGSTAR Study)
招募中1/2 期
- Sarah Cannon Research Institute University of Oklahoma, Oklahoma City
Collection and Storage of Tissue and Blood Samples From Patients With Cancer
招募中观察性研究
- Mercy Hospital Oklahoma City, Oklahoma City
Circulating Tumor DNA Response In Urothelial Cancer
招募中2 期
- OU Health Stephenson Cancer Center, Oklahoma City
Spine Radiosurgery for Symptomatic Metastatic Neoplasms
招募中2 期
- OU Health Stephenson Cancer Center, Oklahoma City
A Study of NX-1607 in Adults With Advanced Malignancies
招募中1 期
- University of Oklahoma, Oklahoma City
其他城市的 转移性癌症试验
- Houston, TX104 项研究
- New York City, NY93 项研究
- Nashville, TN70 项研究
- Boston, MA63 项研究
- Los Angeles, CA57 项研究
- St. Louis, MO54 项研究
- Arlington, VA53 项研究
- Philadelphia, PA46 项研究
- Chicago, IL45 项研究
- San Antonio, TX44 项研究
- Washington, DC43 项研究
- Dallas, TX42 项研究
Oklahoma City的其他研究
- 非小细胞肺癌28 项研究
- 卵巢癌28 项研究
- 子宫内膜癌25 项研究
- 结直肠癌22 项研究
- 前列腺癌21 项研究
- 肺癌19 项研究
- 乳腺癌17 项研究
- 癌症（所有类型）14 项研究
- 急性髓系白血病14 项研究
- 头颈鳞状细胞癌13 项研究
- 膀胱癌11 项研究
- 胰腺癌11 项研究
数据来自 ClinicalTrials.gov，检索日期：2026年10月6日。每项研究自行设定入选标准，由研究团队决定谁能参与。